PRECLINICAL Cro services in
Liver (MASH)
Gubra is industry-leading in translational models of metabolic dysfunction-associated steatohepatitis (MASH) and MASH-driven hepatocellular carcinoma (MASH-HCC). Our automated AI-based histology pipeline enables effective, accurate and objective analysis of drug effects on pivotal clinical endpoints.
Why choose Gubra?
- Expert scientific guidance in MASH
- Clinically translatable models
- GAN DIO-MASH mouse ranked #1 by LITMUS consortium
- Biopsy-enabled stratification of baseline disease
- Profile compounds using clinical trial endpoints
- Tailored study design and rapid initiation
Consult with Michael Feigh
Vice President, Scientific Sales
Choose the right animal model for your MASH-targeted drug candidate.
What is MASH?
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), respectively, are now the replacement terms for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
Industry-leading models for translatability into the clinic
Choosing the right translational model of MASH is crucial for efficacy evaluation and bridging to clinical development. Our GAN DIO-MASH mouse model has been ranked #1 by the LITMUS consortium for its human proximity score and clinical translatability. Our model is already induced and ready to be used for your study. With reference to standard clinical practice, all animals are biopsy-confirmed for stratification of baseline disease which allows for within-subject evaluation of histological outcomes.
Main Offerings
Full metabolic assessment
Biochemical assessment liver & plasma
NAS & fibrosis scoring (pre-post)
Quantitative histology Steatohepatitis & fibrosis
Hepatic transcriptomic profile
GAN DIO-MASH mice readily available
High clinical translatability
Models of MASH
GAN DIO-MASH mouse Efficacy testing
- Top-ranked for human translatability by the LITMUS consortium
- Based on diet-induced obesity with metabolic dysfunction
- Supports moderate to advanced MASH & fibrosis after ≥28 weeks of GAN diet
- Enables MASH-HCC development after ≥48 weeks of GAN diet
- Employs biopsy-confirmed NAFLD Activity Score ≥5 and fibrosis stage F2–F3
- Includes individual pre- and post-treatment histopathological scoring
- Treatment duration: 12–24 weeks
- Validated using clinical late-stage candidates
GAN DIO-MASH mouse POC testing
- Designed as a lead-in model to establish proof-of-concept (POC)
- Supports compound selection for therapeutic candidates
- Enables dose-range testing of interventions
- Suitable for investigating novel combination therapies
- Features a shorter treatment duration of 6–12 weeks
- Incorporates terminal endpoint analysis
- Validated with late-stage clinical candidates
CDAA-HFD mouse
- Recommended by the LITMUS consortium
- Accelerated MASH with progressive advanced fibrosis
- CDAA-HFD administration for ≥12 weeks
- Non-obese phenotype
- Clinical histopathological scoring
- Validated with clinical late-stage drugs
- Therapeutic/Prophylactic intervention
CDAA-HFD rat
- Accelerated MASH with progression to cirrhosis
- CDAA-HFD administration for up to 16 weeks
- Non-obese phenotype
- Clinical histopathological scoring
- Validated with clinical late-stage drugs
- Therapeutic/Prophylactic intervention
Cloud-based data viewer
GubraView
Our cloud-based data viewer GubraView provides instant access to study data as it is uploaded, ensuring seamless monitoring throughout your study. With features for cross-group and cross-study comparisons, GubraView enables informed decision-making with statistical analyses. Accessible across multiple locations, GubraView empowers efficient and collaborative drug development for your whole team.
Related pages
For further information
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650